Ding A H, Porteu F, Sanchez E, Nathan C F
Beatrice and Samuel A. Seaver Laboratory, Department of Medicine, Cornell University Medical College, New York, New York 10021.
J Exp Med. 1990 Mar 1;171(3):715-27. doi: 10.1084/jem.171.3.715.
Exposure of murine and human macrophages and human umbilical vein endothelial cells to micromolar concentrations of five microtubule (MT)-depolymerizing agents (colchicine, nocodazole, podophyllotoxin, vincristine, and vinblastine) resulted in a loss of binding sites for iodinated TNF-alpha. The reduction amounted to 40-60% by 1 h and approximately 75% by 2-4 h. In 1 h, specific binding was reduced 50% by 0.1-5 microM of these drugs at 37 degrees C, but not at 4 degrees C. Inactive isomers of colchicine were ineffective, as were microfilament-destabilizing cytochalasins. The active agents did not compete with TNF-alpha R for binding. Antiserum against TNF-alpha did not neutralize the effect of colchicine and nocodazole. PGE1 and dibutyryl-cAMP could not mimic, and cyclooxygenase inhibitors could not prevent the drug effects. All the binding sites were regenerated within 3 h after removal of nocodazole, which binds tubulin reversibly, whereas little recovery was found even 18 h after the removal of colchicine, which binds tubulin irreversibly. These findings suggested that MT disassembly was responsible for the observed downregulation of TNF-alpha R. The protein synthesis inhibitor cycloheximide inhibited binding of TNF-alpha to a similar extent and with a similar time course as colchicine in the absence of added ligand. Neither drug affected binding of IFN-gamma to macrophages, nor binding of TNF-alpha to human polymorphonuclear leukocytes. Thus, an intact MT network appears to be important in maintenance of the steady state of TNF-alpha R on those cells in which TNF-alpha R turns over rapidly in the absence of ligand. The antiinflammatory actions of MT-depolymerizing agents may result in part from their interference with the ability of such cells to respond to TNF-alpha.
将小鼠和人类巨噬细胞以及人脐静脉内皮细胞暴露于微摩尔浓度的五种微管(MT)解聚剂(秋水仙碱、诺考达唑、鬼臼毒素、长春新碱和长春花碱)中,会导致碘化肿瘤坏死因子-α(TNF-α)的结合位点丧失。1小时后减少量达40%-60%,2-4小时后约为75%。在1小时内,这些药物在37℃时0.1-5微摩尔浓度可使特异性结合减少50%,但在4℃时则不会。秋水仙碱的无活性异构体无效,微丝破坏剂细胞松弛素也无效。活性剂不会与TNF-α受体竞争结合。抗TNF-α抗血清不能中和秋水仙碱和诺考达唑的作用。前列腺素E1和二丁酰环磷腺苷不能模拟,环氧合酶抑制剂也不能阻止药物作用。去除诺考达唑(其与微管蛋白可逆结合)后3小时内所有结合位点均可再生,而去除秋水仙碱(其与微管蛋白不可逆结合)后即使18小时也几乎没有恢复。这些发现表明,微管解聚是观察到的TNF-α受体下调的原因。在没有添加配体的情况下,蛋白质合成抑制剂环己酰亚胺抑制TNF-α结合的程度和时间进程与秋水仙碱相似。两种药物均不影响干扰素-γ与巨噬细胞的结合,也不影响TNF-α与人类多形核白细胞的结合。因此,完整的微管网络对于在没有配体时TNF-α受体快速周转的那些细胞中维持TNF-α受体的稳态似乎很重要。微管解聚剂的抗炎作用可能部分源于它们干扰此类细胞对TNF-α作出反应的能力。